Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background And Objective: Intravesical mitomycin C (MMC) instillations are recommended to prevent recurrence of intermediate-risk non-muscle-invasive bladder cancer (IR-NMIBC); however, the optimal regimen and dose are uncertain. Our aim was to assess the effectiveness of adjuvant MMC and compare different MMC regimens in preventing recurrence.
Methods: We performed a comprehensive search in PubMed, Scopus, and Web of Science in November 2023 for studies investigating recurrence-free survival (RFS) among patients with IR-NMIBC who received adjuvant MMC. Prospective trials with different MMC regimens or other intravesical drugs as comparators were considered eligible.
Key Findings And Limitations: Overall, 14 studies were eligible for systematic review and 11 for meta-analysis of RFS. Estimates of 1-yr, 2-yr, and 5-yr RFS rates were 84% (95% confidence interval [CI] 79-89%), 75% (95% CI 68-82%), and 51% (95% CI 40-63%) for patients treated with MMC induction plus maintenance, and 88% (95% CI 83-94%), 78% (95% CI 67-89%), and 66% (95% CI 57-75%) for patients treated with bacillus Calmette-Guérin (BCG) maintenance, respectively. Estimates of 2-yr RFS rates for MMC maintenance regimens were 76% (95% CI 69-84%) for 40 mg MMC (2 studies) and 66% (95% CI 60-72%) for 30 mg MMC (4 studies). Among the studies included, BCG maintenance provided comparable 2-yr RFS to 40 mg MMC with maintenance (78% vs 76%). RFS did not differ by MMC maintenance duration (>1 yr vs 1 yr vs <1 yr).
Conclusions And Clinical Implications: MMC induction and maintenance regimens seem to provide short-term RFS rates equivalent to those for BCG maintenance in IR-NMIBC. For adjuvant induction and maintenance, 40 mg of MMC appears to be more effective in preventing recurrence than 30 mg. We did not observe an RFS benefit for longer maintenance regimens.
Patient Summary: For patients with intermediate-risk non-muscle-invasive bladder cancer, bladder treatments with a solution of a drug called mitomycin C (MMC) seem to be as effective as BCG (bacillus Calmette-Guérin) in preventing recurrence after tumor removal. Further trials are needed for stronger evidence on the best MMC dose and treatment time.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.euo.2024.06.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Structural and functional investigation of DinG containing a 3'-5' exonuclease domain.
mBio
August 2025
Zhejiang Key Laboratory of Medical Epigenetics, Department of Immunology and Pathogen Biology, School of Basic Medical Sciences, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, Zhejiang, China.
Unlabelled: Damage-inducible gene G (DinG), a bacterial homolog of SF2 helicase, has been extensively studied in . However, the structural and functional characteristics of DinG homologs fused with an N-terminal 3'-5' exonuclease domain, such as DinG (SaDinG), remain unexplored. In this study, we demonstrate that SaDinG possesses 3'-5' exonuclease activity and exhibits 5'-3' helicase activity on diverse DNA substrates, including splayed duplexes, 5'-overhangs, double flaps, bubbles, and gapped duplexes, resolving prior ambiguities about its biochemical functions.
View Article and Find Full Text PDFLogistic and time burdens reported by gynecologic and breast cancer survivors.
BMC Womens Health
June 2025
Department of Obstetrics, Gynecology, and Women's Health, University of Minnesota, 420 Delaware Street SE MMC 395, Minneapolis, MN, 55455, USA.
Background: We assessed the effect of the time requirements of cancer care on other life activities and time burden reduction priorities among breast and gynecologic cancer survivors.
Methods: A total of 224 participants with gynecologic or breast cancer from two cohort studies completed a cross-sectional survey regarding logistic and time burdens of cancer care. We compared agreement with the importance of minimizing travel time, wait time, and trips to the cancer center as well as whether cancer care visits interfered with other activities (dependent care, chores, leisure activities) by employment, education, cancer type, cancer treatment status, dependent status, rural-urban residence, and income.
National Belgian survey on managing non-muscle invasive bladder cancer during Mitomycin and bacillus Calmette-Guerin shortage.
Fr J Urol
August 2025
Department of Urology, Centre Hospitalier Universitaire de Namur, Université Catholique de Louvain, Namur, Belgium.
Introduction: Mitomycin C or bacillus Calmette-Guerin (BCG) intravesical instillations are the more widespread adjuvant treatments following transurethral resection of bladder tumor for intermediate and high-risk non-muscle invasive bladder cancer, but both are regularly in short supply worldwide. This Belgian survey assessed the changes of management during shortage period.
Methods: On behalf of the two national societies of urology in 2023, an anonymous questionnaire was sent to 340 Belgian urologists exploring modifications treatments' practices in shortage period.
Induction Treatment for HIV-Associated Cryptococcal Meningitis: Where Have We Been and Where Are We Going?
Microorganisms
April 2025
Division of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, 420 Delaware Street, SE, MMC 250, Minneapolis, MN 55455, USA.
Cryptococcal meningitis remains a leading cause of morbidity and mortality among individuals with HIV/AIDS, particularly in resource-limited settings. Treatment begins with induction therapy followed by consolidation and maintenance. Evidence related to induction therapy has evolved significantly over the past decade.
View Article and Find Full Text PDFAssociations of various medical nutrition therapy strategies with body composition, and physical and clinical outcomes in acute myeloid leukemia patients undergoing intensive remission-induction treatment: A multicenter prospective correlational study.
Clin Nutr ESPEN
June 2025
Department of Dietetics and Nutrition, Maastricht University Medical Center, P. Debyelaan 25, 6229 HX, Maastricht, the Netherlands; Department of Physiotherapy, Meander Medical Center, Maatweg 3, 3813 TZ, Amersfoort, the Netherlands; Department of Research and Development, Netherlands Comprehensive
Background & Aims: Medical nutrition therapy (MNT) is commonly used in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) undergoing intensive remission-induction treatment to prevent malnutrition, particularly the loss of fat-free mass (FFM)/muscle mass, as well as associated adverse outcomes. However, studies examining the associations of proactive versus wait-and-see approaches toward MNT with nutritional, physical, and clinical outcomes in these patients are lacking. Therefore, this study aimed to explore the associations of these different MNT approaches with body composition changes, as well as physical and clinical outcomes in AML/MDS patients undergoing intensive remission-induction treatment.
View Article and Find Full Text PDF